CoChat

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

Open access
Wong, Jeffrey Sum Lung, Kwok, Gerry Gin Wai, Tang, Vikki, Li, Bryan Cho Wing, Leung, Roland, Chiu, Joanne, Ma, Ka Wing, She, Wong Hoi, Tsang, Josephine, Lo, Chung Mau, Cheung, Tan To, Yau, Thomas · 2021 · Journal for ImmunoTherapy of Cancer

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Background: Programmed cell death protein 1 (PD-1) pathway blockade with immune checkpoint inhibitors (ICIs) is a standard therapy in advanced hepatocellular carcinoma (HCC) nowadays. No strategies to overcome ICI resistance have been described. We aimed to evaluate the use of ipilimumab and anti-PD-1 ICIs (nivolumab or pembrolizumab) combinations in patients with advanced HCC with progression on prior ICIs. Methods: Patients with advanced HCC with documented tumor progression on prior ICIs and subsequently received ipilimumab with nivolumab/pembrolizumab were analyzed. Objective response rate (ORR), median duration of response (DOR), time-to-progression (TTP), overall survival (OS), and treatment-related adverse events (TRAEs) were assessed. Results: Twenty-five patients were included. The median age was 62 (range: 51–83). About 68% were of Child-Pugh (CP) Grade A and 48% had primary resistance to prior ICI. At median follow-up of 37.7 months, the ORR was 16% with a median DOR of 11.5 months (range: 2.76–30.3). Three patients achieved complete response. The median TTP was 2.96 months (95% CI: 1.61 to 4.31). Median OS was 10.9 months (95% CI: 3.99 to 17.8) and the 1 year, 2 year and 3 year survival rates were 42.4%, 32.3% and 21.6%, respectively. The ORR was 16.7% in primary resistance group and 15.4% in acquired resistance group (p=1.00). All responders were of CP A and Albumin-Bilirubin (ALBI) Grade 1 or 2. CP and ALBI Grades were significantly associated with OS (p=0.006 and p<0.001, respectively). Overall, 52% of patients experienced TRAEs and 12% experienced Grade 3 or above TRAEs. Conclusions: Ipilimumab and nivolumab/pembrolizumab can achieve durable antitumor activity and encouraging survival outcomes with acceptable toxicity in patients with advanced HCC who had prior treatment with ICIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-001945

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Kaplan-Meier analysis of OS. Dotted lines plot time points, percentages represent survival rates. OS, overall survival.
Figure 1 Kaplan-Meier analysis of OS. Dotted lines plot time points, percentages represent survival rates. OS, overall survival.CC BY-NC · PubMed Central
Figure 2 Kaplan-Meier analysis of OS by resistance pattern to prior ICI. Level of significance: p=0.55 (log-rank test). ICI, immune checkpoint inhibitor; OS, overall survival.
Figure 2 Kaplan-Meier analysis of OS by resistance pattern to prior ICI. Level of significance: p=0.55 (log-rank test). ICI, immune checkpoint inhibitor; OS, overall survival.CC BY-NC · PubMed Central
Figure 3 Kaplan-Meier analysis of OS by CP Grade. Level of significance: p=0.006 (log-rank test). CP, Child-Pugh; OS, overall survival.
Figure 3 Kaplan-Meier analysis of OS by CP Grade. Level of significance: p=0.006 (log-rank test). CP, Child-Pugh; OS, overall survival.CC BY-NC · PubMed Central
Figure 4 Kaplan-Meier analysis of OS by ALBI Grade. Level of significance: p<0.001 (log-rank test). ALBI, Albumin-Bilirubin; OS, overall survival.
Figure 4 Kaplan-Meier analysis of OS by ALBI Grade. Level of significance: p<0.001 (log-rank test). ALBI, Albumin-Bilirubin; OS, overall survival.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 142

Metadata

Authors
Wong, J. S. L., Kwok, G. G. W., Tang, V., Li, B. C. W., Leung, R., Chiu, J., Ma, K. W., She, W. H., Tsang, J., Lo, C. M., Cheung, T. T., & Yau, T.
Affiliations
  • Queen Mary Hospital (CN)
  • Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
  • Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
Corresponding author
Yau, Thomas
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2021-02
Volume
9
Issue
2
Pages
e001945
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3128927131
Cited by
142
References
34
Citations by year
2026: 16 · 2025: 27 · 2024: 24 · 2023: 33 · 2022: 27 · 2021: 15
FWCI
9.00
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Research Grant Council Theme Based Research Fund (T12-704/16-R)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
hepatocellular carcinoma, ipilimumab, nivolumab, pembrolizumab, immune checkpoint inhibitors, anti-PD-1 therapy, immune checkpoint inhibitor resistance, combination immunotherapy, objective response rate, overall survival, Child-Pugh score, ALBI score, treatment-related adverse events, durable response, treatment toxicity, progression-free survival, treatment duration, cost-effectiveness
MeSH terms
Ipilimumab, Nivolumab, Immune Checkpoint Inhibitors, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Retrospective Studies, Time Factors, Salvage Therapy, Treatment Outcome, Disease Progression, Drug Resistance, Neoplasm, Tumor Microenvironment, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. https://app.cochat.ai/papers/10.1136/jitc-2020-001945
The paper
Wong, J. S. L., Kwok, G. G. W., Tang, V., Li, B. C. W., Leung, R., Chiu, J., Ma, K. W., She, W. H., Tsang, J., Lo, C. M., Cheung, T. T., & Yau, T. (2021). Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-001945

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.